Hemab Therapeutics 控股
COAG
30.07
-2.45
-7.53%
Hemab Therapeutics 控股
US · COAG
#3007 按市值排名
上市于 2026
30.07
-2.45
-7.53%
实时 - 追踪5344个代码 - 心跳于424秒前
· 2026-10-16 19:30
最新新闻
-
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42\u5e02\u573a\u8d44\u8baf · 2026/6/30
-
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
评级变动
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36\u5e02\u573a\u8d44\u8baf · 2026/5/26
-
评级变动
Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy From WedbushTipRanks · 2026/6/30
-
评级变动
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39\u5e02\u573a\u8d44\u8baf · 2026/6/9
-
评级变动
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42\u5e02\u573a\u8d44\u8baf · 2026/5/26
-
Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy From WedbushTipRanks · 2026/8/12
-
评级变动
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50\u5e02\u573a\u8d44\u8baf · 2026/5/26
-
评级变动
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $40\u5e02\u573a\u8d44\u8baf · 2026/6/27
-
评级变动
H.C. Wainwright Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $40\u5e02\u573a\u8d44\u8baf · 2026/6/17
-
评级变动
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39\u5e02\u573a\u8d44\u8baf · 2026/5/26
-
评级变动
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47\u5e02\u573a\u8d44\u8baf · 2026/7/14
-
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $55\u5e02\u573a\u8d44\u8baf · 2026/7/14
-
评级变动
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52\u5e02\u573a\u8d44\u8baf · 2026/7/13
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Hemab Therapeutics 控股 讨论区 0 条评论